DDInter814 DDInter1259
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Rosoxacin
Rosoxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Pefloxacin
Pefloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Lomefloxacin {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Nalidixic acid
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Norfloxacin
Norfloxacin {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Nalidixic acid
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Enoxacin {u} (Compound) upregulates {v} (Gene) HERC6
HERC6 {u} (Gene) is upregulated by {v} (Compound) Nalidixic acid
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofarabine
Clofarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin (Compound) resembles Nalidixic acid (Compound)
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Nalidixic acid (Compound)
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin (Compound) resembles Rosoxacin (Compound) and Rosoxacin (Compound) resembles Nalidixic acid (Compound)
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) resembles Nalidixic acid (Compound)
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) resembles Nalidixic acid (Compound)
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Pefloxacin (Compound) and Pefloxacin (Compound) resembles Nalidixic acid (Compound)
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Nalidixic acid (Compound)
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Nalidixic acid (Compound)
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) upregulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Nalidixic acid (Compound)
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin (Compound) resembles Nalidixic acid (Compound)